ES2111579T3 - Preparaciones de factor viii estabilizadas. - Google Patents

Preparaciones de factor viii estabilizadas.

Info

Publication number
ES2111579T3
ES2111579T3 ES92104944T ES92104944T ES2111579T3 ES 2111579 T3 ES2111579 T3 ES 2111579T3 ES 92104944 T ES92104944 T ES 92104944T ES 92104944 T ES92104944 T ES 92104944T ES 2111579 T3 ES2111579 T3 ES 2111579T3
Authority
ES
Spain
Prior art keywords
factor viii
viii preparations
stabilized factor
stabilized
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92104944T
Other languages
English (en)
Other versions
ES2111579T4 (es
Inventor
Wilfried Freudenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centeon Pharma GmbH
Original Assignee
Centeon Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6429102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2111579(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centeon Pharma GmbH filed Critical Centeon Pharma GmbH
Publication of ES2111579T3 publication Critical patent/ES2111579T3/es
Application granted granted Critical
Publication of ES2111579T4 publication Critical patent/ES2111579T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PREPARACIONES DE FACTOR VIII ESTABILIZADAS. LA INVENCION TRATA DE SOLUCIONES ESTABILIZADAS CON ACTIVIDAD DE COAGULACION F VIII, UN PROCEDIMIENTO PARA SU PRODUCCION Y TAMBIEN DE SU UTILIZACION.
ES92104944T 1991-04-09 1992-03-21 Preparaciones de factor viii estabilizadas. Expired - Lifetime ES2111579T4 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4111393A DE4111393A1 (de) 1991-04-09 1991-04-09 Stabilisierte faktor viii-praeparationen
DE4111393 1991-04-09

Publications (2)

Publication Number Publication Date
ES2111579T3 true ES2111579T3 (es) 1998-03-16
ES2111579T4 ES2111579T4 (es) 2011-12-29

Family

ID=6429102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92104944T Expired - Lifetime ES2111579T4 (es) 1991-04-09 1992-03-21 Preparaciones de factor viii estabilizadas.

Country Status (12)

Country Link
US (1) US5565427C1 (es)
EP (1) EP0508194B1 (es)
JP (2) JP3777467B2 (es)
KR (1) KR100231398B1 (es)
AT (1) ATE160942T1 (es)
AU (1) AU651188B2 (es)
CA (1) CA2065553C (es)
DE (2) DE4111393A1 (es)
DK (1) DK0508194T3 (es)
ES (1) ES2111579T4 (es)
GR (1) GR3025873T3 (es)
IE (1) IE921124A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229931A1 (es) * 2003-10-03 2005-04-16 Probitas Pharma, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9302006D0 (sv) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab Protein formulation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
ES2321297T3 (es) 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
DE10333317A1 (de) † 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
PL1750733T3 (pl) 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
EP2264162A1 (en) * 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2679107C (en) * 2007-02-23 2018-01-16 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
EP2150264A4 (en) 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
KR101691070B1 (ko) * 2008-09-03 2016-12-29 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
PL2616090T3 (pl) * 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
US8916352B2 (en) 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
CN103562410B (zh) 2011-04-08 2016-09-28 伯乐实验室公司 具有降低的非特异性活性的sso7-聚合酶缀合物
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
JP2014138614A (ja) * 2014-04-09 2014-07-31 Sk Chemicals Co Ltd 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
JP4021982B2 (ja) * 1998-03-03 2007-12-12 信越化学工業株式会社 ハイブリッド型ウイグラ

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229931A1 (es) * 2003-10-03 2005-04-16 Probitas Pharma, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Also Published As

Publication number Publication date
JP3777467B2 (ja) 2006-05-24
JP3809501B2 (ja) 2006-08-16
JPH0597702A (ja) 1993-04-20
US5565427A (en) 1996-10-15
AU651188B2 (en) 1994-07-14
ES2111579T4 (es) 2011-12-29
DE59209051D1 (de) 1998-01-22
ATE160942T1 (de) 1997-12-15
EP0508194B1 (de) 1997-12-10
US5565427C1 (en) 2002-07-23
JP2002097199A (ja) 2002-04-02
GR3025873T3 (en) 1998-04-30
CA2065553A1 (en) 1992-10-10
CA2065553C (en) 2003-06-10
KR100231398B1 (ko) 1999-11-15
DE4111393A1 (de) 1992-10-15
DK0508194T3 (da) 1998-08-24
AU1470292A (en) 1992-10-15
KR920019371A (ko) 1992-11-19
EP0508194A1 (de) 1992-10-14
IE921124A1 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
US5565427C1 (en) Stabilized factor viii preparations
DE69130020D1 (de) Stabilisierte, retinoide enthaltende hautpflegepräparate
DE69202739D1 (de) Gemischtes Alkylmethylsiloxane zur Hautpflege.
NO924895L (no) Blekekatalysator, samt fremgangsmaate for bleking
FI915262A0 (fi) Hydrodesulforiseringsfoerfarande i flere steg.
DE68906293D1 (de) Zufuhr von kohlendioxid.
IT218185Z2 (it) Irroratore oscillante perfezionato.
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
DE68913090D1 (de) Modifizierter menschlicher PSTI.
FI893366L (fi) 4-piperidylmetyl-2,3-dihydro-1h -isoindol- och 2,3,4,5-tetrahydro-1h-bensasepinderivat, deras framstaellning och terapeutiska anvaendning.
ATE121400T1 (de) Pyridyl-methylenamino-1,2,4-triazinone.
FI893714A7 (fi) 2-amino-4-morfolino-6-propyl -1,3,5-triaziner.
IT8921236A0 (it) Procedimento per produrre pezzi stampati e dispositivo per l'esecuzione del procedimento.
FI892748L (fi) Vaextregleringsfoerfarande.
IT8919814A0 (it) Dispositivo di bloccaggio e regolazione, particolarmente per compassi da disegnatore.
ES1011526Y (es) Invernadero perfeccionado.
ES1008212Y (es) Biberon desechable perfeccionado.
IT208775Z2 (it) Siringa per l'anestesia intraligamentosa.
ITTO930116A0 (it) Procedimento per preparare uan soluzione contentente semitrichinoyl, con proprieta' terapeutiche.
ES1007581Y (es) Biberon desechable.
MX9203464A (es) 1-aminometil-1,2,3,4-tetrahidronaftalenos.
IT9003745A0 (it) Ago a farfalla di sicurezza per uso medicale.
ES1006662Y (es) Mesa perfeccionada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 508194

Country of ref document: ES